Loading stock…

Bio-Techne Corporation (TECH) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Bio-Techne Corporation

TECHMarket cap $11BPrice $72.4

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Makes the antibodies, proteins, and reagents scientists use to develop drugs and diagnose disease. Its tools have been cited in over 500,000 published research papers, making it the quiet backbone behind countless biotech breakthroughs.

In Bastion Portfolios?

52W Return+18%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+2%4

Revenue Forecast

Rev CAGR (1y)+4%4

Rev CAGR (3y)+8%6

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+1+71%10

EPS Growth Y+2+13%7

EPS Growth Y+3+7%6

Quality

Margins

EBIT Margin23%8

Net Income Margin15%7

Free Cash Flow Margin22%8

Debt

Net Debt/EBITDA0.19

Efficiency

ROE9%4

ROA7%7

Earnings Stability55

GEAR+AVERAGE54

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)362

P/E Ratio (Forward 3y)302

P/BV5.43

EV Multiples

EV/EBITDA Fwd252

EV/EBIT Fwd272

Yield

Free Cash Flow Yield2.3%4

Dividend Yield0.4%2

Momentum

Short term

1 month return0%8

3 month return+3%7

YTD return+24%8

Mid term

Price vs 52wHigh100%10

1 year return+23%7

Long term

3 year return+8%3

5 year return-39%2

Risk Shield

Price Risk

Beta0.85

Volatility44%4

Free Cash Flow

Free Cash Flow Margin22%8

Free Cash Flow Yield2.3%4

Quality

ROCE11%6

Earnings Stability55

Net Debt/EBITDA0.19

02Growth

Is it actually growing, and how fast?

TECHBio-Techne

Revenue FY26$1.2B

GROWTH RATING↗

AVERAGE56 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+2%4

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+71%10

EPS growth, FY28E+13%7

EPS growth, FY29E+7%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 2%/yr over the last 3 years and is set to grow 8%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 13%/yr vs revenue 8%/yr).

WATCH

A mid-pack grower, ahead of 56% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE64 / 100

SHORT-TERM RETURNS▾SCORE

1-month return0%8

3-month return+3%7

YTD return+24%8

MID & LONG-TERM▾SCORE

% of 52-week high100%10

1-year return+23%7

3-year return+8%3

5-year return-39%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 23% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+3%) and so far this year (+24%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+7.8% over three years and -39% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Bio-Techne. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TECHBio-Techne

Revenue FY26$1.2B

GROWTH RATING↗

AVERAGE56 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+2%4

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+71%10

EPS growth, FY28E+13%7

EPS growth, FY29E+7%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 2%/yr over the last 3 years and is set to grow 8%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 13%/yr vs revenue 8%/yr).

WATCH

A mid-pack grower, ahead of 56% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE64 / 100

SHORT-TERM RETURNS▾SCORE

1-month return0%8

3-month return+3%7

YTD return+24%8

MID & LONG-TERM▾SCORE

% of 52-week high100%10

1-year return+23%7

3-year return+8%3

5-year return-39%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 23% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+3%) and so far this year (+24%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+7.8% over three years and -39% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Bio-Techne. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community